

FROM COHORTS TO CLINICS:

THE NEW LANDSCAPE OF GLOBAL HEALTHCARE

PRECISE-IHCC CONFERENCE

21 – 23 AUGUST 2024

E-PROGRAMME



Content Page

About PRECISE-IHCC Conference 2024.....	3
Conference Aims	4
Organisers.....	5
Organising and Scientific Committee	6
Welcome Message (Option 1).....	7
Welcome Message (Option 2).....	8
Conference Floorplan.....	9
Programme	10
Overview Of Sessions	19
Accepted Abstracts.....	27
Sponsors and Partners.....	32

About PRECISE-IHCC Conference 2024

Jointly organised by **Precision Health Research, Singapore (PRECISE)** and the **International Health Cohorts Consortium (IHCC)**, the conference will bring together some 600 thought leaders, clinicians, scientists, biotechs, and patient advocacy associations from across the world who are at the forefront of precision medicine and public health innovation.

Themed “**From Cohorts to Clinics: The New Landscape of Global Healthcare**”, the conference seeks to address the challenges and opportunities in translating advances in precision medicine into tangible enhancements in patient care and reshape the landscape of modern healthcare. It also aims to catalyse and promote cross-population cohort research and design cross-cohort pilot projects to address various global challenges.

The three-day conference will be held **on-site** from **21 to 23 August 2024** in **Singapore**.

Conference Aims

Through this conference we aim to:

Aim #1 Encourage Scientific Exchange: Thought leaders, policymakers, researchers, and industry stakeholders in the field of precision medicine will have a platform to share their insights, discoveries and findings, facilitating cross-pollination of ideas and methodologies.

Aim #2 Translate Precision Science to Impact Patients: Provide a unique opportunity to bring together the scientific community, clinicians, patients and other stakeholders to integrate scientific advances into patient care, reshaping the landscape of modern healthcare.

Aim #3 Showcase Global Advancements in Genomic and Precision Medicine: Showcase cutting-edge, cost-effective, and clinically effective healthcare solutions and demonstrate a collective dedication to making these advancements accessible, equitable, and beneficial across different populations worldwide.

Aim #4 Bring Diverse Perspectives on Global Challenges: Bring together esteemed speakers from global precision medicine programs across the globe, to provide diverse insights into the latest developments in this rapidly evolving field.

Aim #5 Champion Early-Career Scientists in Genomic and Precision Medicine: Provide emerging researchers with opportunities to showcase their work, gain invaluable insights from the frontiers of genomic research and precision medicine, and engage with leading professionals.

Aim #6 Enhance Cohort Studies and Biobank Integration for Translational Impact: Spotlight the critical role of extensive cohorts and biobanks in advancing genomic and precision medicine to ensure that innovations reach the bedside with ethical integrity and global inclusivity.

Jointly Organised By

Precision Health Research, Singapore (PRECISE) is the central entity set up to coordinate a whole of government effort to implement Phase II of Singapore's three-phase **National Precision Medicine (NPM) programme**.

It aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions. NPM Phase II will also enhance the breadth and depth of the Precision Medicine-related industry by attracting and anchoring overseas companies in Singapore, while yielding new opportunities for home-grown companies.

PRECISE is a programme under the Consortium for Clinical Research and Innovation, Singapore (CRIS).

For more information, visit www.npm.sg



PRECISE
Precision Health Research
Singapore

The **International Health Cohorts Consortium (IHCC)** aims to create a global platform for translational research – cohort to bedside and cohort to bench – informing the biological and genetic basis for disease and improving clinical care and population health.

It brings large cohorts together to encourage data sharing, improve efficiencies and maximise benefits in addressing scientific questions none could answer alone. To address the value and challenges of combining large cohort data across borders, the IHCC has formed two working groups:

1. Scientific Strategy and Cohorts Enhancement; and
2. Data Standards and Infrastructure.

For more information, please visit <https://ihccglobal.org>



International Health
Cohorts Consortium

Organising Committee



Ms Lee Yee Shuan

Consortium for Clinical Research and Innovation, Singapore (CRIS) and Precision Health Research, Singapore (PRECISE)



Mr Chris Nelson

Global Genomic Medicine Collaborative (GGMC)



Ms Chisom Nwaneri

International Health Cohorts Consortium (IHCC)



Dr Seow Shih Wee

Precision Health Research, Singapore (PRECISE)



Dr Scott Sundseth

International Health Cohorts Consortium (IHCC)



Mr Tan Jia En

Precision Health Research, Singapore (PRECISE)



Ms Meredith Towery

Global Genomic Medicine Collaborative (GGMC)

Scientific Committee



Prof Nahla Afifi

International Health Cohorts Consortium (IHCC)



Dr Arash Etemadi

National Cancer Institute, NIH, U.S.A.



Prof Segun Fatumo

Queen Mary University of London



Adj Asst Prof Max Lam

Precision Health Research, Singapore (PRECISE)



Clinical A/Prof Tan Ee Shien

Precision Health Research, Singapore (PRECISE)



Dr Ricardo A. Verdugo

Department of Basic-Applied Oncology, University of Chile, Chile and Faculty of Medicine, University of Talca, Chile

The committee members are arranged in alphabetical order based on their last names.



Welcome Message (Option 1)



Prof Patrick Tan
Executive Director
Precision Health Research, Singapore

[Insert Photo]

[Sal][Name]
[Designation]
[Organisation]

Welcome to the PRECISE-IHCC Conference 2024!

We are thrilled to have you join us for this groundbreaking event, where innovation and collaboration converge to shape the future of healthcare. Over the next few days, you'll have the opportunity to engage with leading experts, explore cutting-edge research, and discover transformative strategies that are redefining personalized medicine.

This conference serves as a platform for sharing knowledge, fostering connections, and advancing our collective mission to tailor medical care to the individual. Your participation is crucial in driving forward these initiatives and making a tangible impact on patient outcomes worldwide.

Thank you for being part of this journey towards a more precise and effective approach to medicine. We look forward to your contributions and hope you find the sessions both inspiring and insightful.

We are thrilled to welcome you to this year's PRECISE-IHCC Conference 2024, where innovation meets impact. This gathering brings together the brightest minds from across the globe to explore cutting-edge advancements in personalized healthcare. Our aim is to foster collaboration and share knowledge that will drive forward the future of medicine.

Over the coming days, you will have the opportunity to engage with leading experts, participate in thought-provoking discussions, and gain insights into the latest research and technologies. Your participation is crucial in shaping the future of precision medicine, and we encourage you to actively engage with the sessions and networking opportunities.

Thank you for joining us and contributing to the advancement of precision medicine. We look forward to a productive and inspiring event.

Welcome Message (Option 2)

Welcome to the Precision-IHCC Conference 2024!

We are thrilled to have you join us for this groundbreaking event, where innovation and collaboration converge to shape the future of healthcare. Over the next few days, you'll have the opportunity to engage with leading experts, explore cutting-edge research, and discover transformative strategies that are redefining personalized medicine.

This conference serves as a platform for sharing knowledge, fostering connections, and advancing our collective mission to tailor medical care to the individual. Your participation is crucial in driving forward these initiatives and making a tangible impact on patient outcomes worldwide.

Thank you for being part of this journey towards a more precise and effective approach to medicine. We look forward to your contributions and hope you find the sessions both inspiring and insightful.



Prof Patrick Tan

Executive Director

Precision Health Research,
Singapore

We are thrilled to welcome you to this year's PRECISE-IHCC Conference 2024, where innovation meets impact. This gathering brings together the brightest minds from across the globe to explore cutting-edge advancements in personalized healthcare. Our aim is to foster collaboration and share knowledge that will drive forward the future of medicine.

[Insert Photo]

[Sal][Name]

[Designation]

[Organisation]

Over the coming days, you will have the opportunity to engage with leading experts, participate in thought-provoking discussions, and gain insights into the latest research and technologies. Your participation is crucial in shaping the future of precision medicine, and we encourage you to actively engage with the sessions and networking opportunities.

Conference Floorplan

Conference Venue:


One Farrer Hotel

1 Farrer Park Station Road Singapore 217562

- Grand Ballroom – Level 6
- Meeting Room – Level 6
- Wisteria & Camellia Villa – Level 6

* Not drawn to scale

* Floorplan subject to change without prior notice



Sponsor Booths

B01 Agilent Technologies

B02 Nightingale Health

B03 Oxford Nanopore Technologies

B04 Illumina

B05 BC Platforms

B06 MGITech

B07 Olink

B08 Novartis

B09 Sanofi

B10 JLABS

B11 Macrogen Asia Pacific

B12 NovogeneAIT Genomics


B13 PacBio

B14 SomaLogic

B15 Inqaba Biotech

Programme: Day 1 – 21 August 2024 (Wednesday)

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
9.00 am - 9.15 am	Welcome Address <ul style="list-style-type: none"> ▷ Prof Patrick Tan <i>Precision Health Research, Singapore</i> Opening Address by Guest of Honour <ul style="list-style-type: none"> ▷ Dr Janil Puthucheary <i>Senior Minister of State, Ministry of Communications and Information & Ministry of Health</i> 		
9.15 am - 9.45 am	Plenary 1: NHS Genomic Medicine Service – From Cohorts to Clinics <ul style="list-style-type: none"> ▷ Prof Dame Sue Hill <i>NHS England</i> 		
9.45 am - 10.15 am	Teabreak Networking Session (Foyer)		
Session 1			
10.15 am - 11.40 am	Ethics and Policy <ul style="list-style-type: none"> ▷ 10.15 am - 10.35 am The Public Interest: Privacy vs Utility <ul style="list-style-type: none"> ▷ Prof Julian Savulescu <i>National University of Singapore</i> ▷ 10.35 am - 10.55 am Who is ELSA? Why does ELSI matter?! <ul style="list-style-type: none"> ▷ Dr Michaela Mayrhofer <i>BBMRI-ERIC</i> ▷ 10.55 am - 11.15 am Diversity, representation and bias in precision medicine <ul style="list-style-type: none"> ▷ Dr Angela Ballantyne <i>University of Otago</i> ▷ 11.15 am - 11.40 am Group Q&A Moderator: <ul style="list-style-type: none"> ▷ Prof Nicki Tiffin <i>South African National Bioinformatics Institute, University of the Western Cape</i> 		
11.40 am - 12.00 pm	Poster Session (Grand Ballroom & Foyer)		
12.00 pm - 1.30 pm	Parallel Track 1: Lunch Time Industry Talk	Parallel Track 2: Lunch Time Industry Talk	Parallel Track 3: Lightning Talk (Early Career Scientist)
▷ 12.20 pm – 12.55 pm	Presentation by PacBio: Personalized Medicine with PacBio Long Reads: Experience from the Estonian Biobank <ul style="list-style-type: none"> ▷ Prof Lili Milani <i>Estonia Biobank, Estonian Genome Center, University of Tartu</i> 	Presentation by BC Platforms	<ul style="list-style-type: none"> ▷ Oral Presenter 1 (15mins) ▷ Oral Presenter 2 (15mins) ▷ Oral Presenter 3 (15mins) ▷ Oral Presenter 4 (15mins) ▷ Oral Presenter 5 (15mins)
▷ 12.55 pm – 1.20 pm	Presentation by MGI	Presentation by SomaLogic	



Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
Session 2			
1.30 pm - 2.00 pm	Plenary 2: Singapore National Precision Medicine Programme - Value Creation for Health and the Economy <ul style="list-style-type: none"> ▷ Prof Patrick Tan <i>Precision Health Research, Singapore</i> 		
2.00 pm - 3.20 pm	Parallel Track 1: Complex Traits/Variant Resolution <ul style="list-style-type: none"> ▷ 2.00 pm - 2.20 pm Single-cell RNA-seq dataset integration without loss of unique rare cell populations ▷ Prof Wong Limsoon <i>National University of Singapore</i> ▷ 2.20 pm - 2.40 pm Realising the Dream of Precision Medicine in Schizophrenia ▷ Dr Jimmy Lee <i>Institute of Mental Health</i> ▷ 2.40 pm - 3.00 pm ▷ Dr Ammira Al-Shabeb Akil <i>Sidra Medicine</i> ▷ 3.00 pm - 3.20 pm Group Q&A Moderator: ▷ Dr Lim Weng Khong <i>Duke-NUS Medical School</i> 	Parallel Track 2: Data Driven Discovery <ul style="list-style-type: none"> ▷ Our Future Health: A world leading resource for population health, genomics and prevention research ▷ Dr Raghib Ali <i>Our Future Health</i> ▷ Decoding Cellular Intelligence To Accelerate Drug Discovery ▷ Dr Rob Yang <i>CartaBio Inc</i> ▷ Advancing Genomic Medicine through Global Data Sharing and Collaboration ▷ Dr Heidi Rehm <i>Massachusetts General Hospital and Broad Institute</i> ▷ Group Q&A Moderator: ▷ Dr Thomas Keane <i>EMBL- European Bioinformatics Institute</i> 	
3.20 pm - 4.00 pm	Teabreak Networking Session (Foyer)		
Session 3			
4.00 pm - 5.20 pm	Parallel Track 1: Cancer Genetics	Parallel Track 2: Genomic Screening	
▷ 4.00pm – 4.20pm	Cancer Predisposition in Singapore: Insights from SG10K and beyond <ul style="list-style-type: none"> ▷ Prof Joanne Ngeow <i>National Cancer Centre Singapore</i> 	▷ Dr Chien Yin Hsiu <i>National Taiwan University</i>	
▷ 4.20pm – 4.40pm	Integrating Cohorts and Multi-Omics to Capture the Earliest Determinants of Cancer and Aging <ul style="list-style-type: none"> ▷ Dr Philip Awadalla <i>Ontario Institute for Cancer Research</i> 	What do we know about expanded reproductive carrier screening? <ul style="list-style-type: none"> ▷ Prof Martin Delatycki <i>Murdoch Children's Research Institute</i> 	
▷ 4.40pm – 5.00pm	Genetic Risk Assessment in Cancer: Towards Personalized Risk Management in Asian Populations <ul style="list-style-type: none"> ▷ Dr Ho Weang Kee <i>University of Nottingham Malaysia/Cancer Research Malaysia</i> 	Ethical issues in genomic screening <ul style="list-style-type: none"> ▷ Prof Thong Meow-Keong <i>Universiti Tunku Abdul Rahman</i> 	
▷ 5.00pm – 5.20pm	Group Q&A Moderator: ▷ Dr Arash Etemadi <i>National Cancer Institute, NIH</i>	Group Q&A Moderator: ▷ Dr Tan Ee Shien <i>Precision Health Research, Singapore</i>	

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
5.20 pm		End of Programme Day 1	

Programme: Day 2 – 22 August 2024 (Thursday)

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
Session 4			
9.00 am - 9.30 am	Plenary 3: Implementing genomic medicine into clinical practice – a national and international perspective <ul style="list-style-type: none"> ▷ Prof Kathryn North <i>Murdoch Children's Research Institute</i> 		
9.30 am - 10.55 am	Biobanks for Precision Medicine <ul style="list-style-type: none"> ▷ FinnGen, an example of a Northern European large scale biobank study <ul style="list-style-type: none"> ▷ Prof Aarno Palotie <i>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland and Broad Institute and Massachusetts General Hospital, Boston, USA</i> ▷ The All of Us Research Program <ul style="list-style-type: none"> ▷ Dr Geoffrey Ginsburg <i>All of Us Research Program, National Institutes of Health</i> ▷ Challenge for Personalized Healthcare: the Tohoku Medical Megabank Project <ul style="list-style-type: none"> ▷ Prof Masayuki Yamamoto <i>Tohoku University Tohoku Medical Megabank Organization (ToMMo)</i> ▷ Group Q&A Moderator: <ul style="list-style-type: none"> ▷ Prof Nahla Afifi <i>International Health Cohorts Consortium (IHCC)</i> 		
10.55 am - 11.15a m	Teabreak Networking Session (Foyer)		
Session 5			
11.15am - 12.40pm	Pharmacogenomics <ul style="list-style-type: none"> ▷ Rethinking Pharmacogenomics - Implementing Pre-emptive Pharmacogenomics in a Singapore Healthcare System <ul style="list-style-type: none"> ▷ Dr Elaine Lo Ah Gi <i>National University Hospital</i> ▷ Pharmacogenomics implementation: towards precision medicine <ul style="list-style-type: none"> ▷ Prof Collet Dandara <i>University of Cape Town</i> ▷ Clinical pharmacogenomics implementation in Thailand: a dream come true <ul style="list-style-type: none"> ▷ Prof Chonlaphat Sukasem <i>Ramathibodi Hospital, Mahidol University</i> ▷ Group Q&A Moderator: <ul style="list-style-type: none"> ▷ Mr Grant M. Wood <i>Global Genomic Medicine Collaborative (GGMC)</i> 		

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
12.40 pm - 2.00 pm	Parallel Track 1: Lunch Time Industry Talk	Parallel Track 2: Lunch Time Industry Talk	Parallel Track 3: Lightning Talk (Early Career Scientist)
▷ 1.00 pm – 1.25 pm	Presentation by Illumina: AI for precision medicine and drug discovery ▷ Dr Kyle Farh <i>Illumina</i>	Presentation by Olink	▷ Oral Presenter 1 (15mins) ▷ Oral Presenter 2 (15mins) ▷ Oral Presenter 3 (15mins) ▷ Oral Presenter 4 (15mins) ▷ Oral Presenter 5 (15mins)
▷ 1.25 pm – 1.50 pm		Presentation by Oxford Nanopore Technologies: The Era of Complete Genomes ▷ Ms Cora Vacher <i>Oxford Nanopore Technologies</i>	
Session 6			
2.00 pm - 3.20 pm	Parallel Track 1: Rare Diseases	Parallel Track 2: Biobanks for Precision Medicine	Parallel Track 3: Fireside Chat (ECI)
▷ 2.00 pm - 2.20 pm	Singapore Undiagnosed Research Endeavour ▷ Dr Saumya Jamuar <i>KK Women's and Children's Hospital</i>	▷ Prof John Chambers <i>Precision Health Research, Singapore</i>	
▷ 2.20 pm - 2.40 pm	Genomics of Rare Diseases for Health Equity in Mexico and Latin America ▷ Dr Claudia Gonzaga-Jauregui <i>International Laboratory for Human Genome Research, UNAM</i>	Harnessing the power of proteomics in biobanks to advance precision health ▷ Prof Chen Zhengming <i>University of Oxford</i>	
▷ 2.40 pm - 3.00 pm	Implementing a Rare Diseases Program in Chile. What have we learned? ▷ Dr Gabriela Repetto <i>Universidad del Desarrollo</i>	Genetic analysis of quantitative traits in the Taiwan Biobank ▷ Dr Lin Yen-Feng <i>National Health Research Institutes, Taiwan</i>	
▷ 3.00 pm - 3.20 pm	Group Q&A Moderator: ▷ Prof Duangrurdee Wattanasirichaigoon <i>Faculty of Medicine Ramathibodi Hospital, Mahidol University</i>	Group Q&A Moderator: ▷ Dr Geoffrey Ginsburg <i>All of Us Research Program, National Institutes of Health</i>	
3.20 pm - 4.00 pm	Teabreak Networking Session (Foyer)		
Session 7			
4.00 pm - 5.20 pm	Parallel Track 1: Training/Early Career Scientists	Parallel Track 2: Genomic/Precision Medicine for Therapeutic R&D	
▷ 4.00 pm - 4.20 pm	Nurturing the physician-scientists needed to make precision medicine a reality ▷ Dr Sharon Plon <i>Baylor College of Medicine</i>	The Together for CHANGE™ Initiative: A Public-Private Partnership Expanding Genomics Research ▷ Dr Lyndon Mitnaul <i>Regeneron Genetics Center</i>	
▷ 4.20 pm - 4.40 pm	Nanocourse: Providing Genomics Researchers with Clinical Perspective ▷ Prof Richard Haspel <i>Beth Israel Deaconess Medical Center and Harvard Medical School</i>	Transforming Drug Discovery with large-scale genomics ▷ Dr Guillermo Del Angel <i>AstraZeneca</i>	
▷ 4.40 pm - 5.00 pm	▷ Dr Victoria Nembaware <i>University of Cape Town</i>	Embedding multimodal discovery in pharma R&D ▷ Dr Mark McCarthy <i>Genentech</i>	

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
▷ 5.00 pm - 5.20 pm	Group Q&A Moderator: ▷ Prof Michele Ramsay <i>University of the Witwatersrand</i>	Group Q&A Moderator: ▷ Dr Scott Sundseth <i>International Health Cohorts Consortium (IHCC)</i>	
5.20 pm	End of Programme Day 2		

Programme: Day 3 – 23 August 2024 (Friday)

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
Session 8			
9.00 am - 9.30 am	Plenary Talk 4: Implementing Genomic Medicine Towards Universal Health Coverage for All People <ul style="list-style-type: none"> ▷ Prof Vajira Dissanayake <i>University of Colombo, Sri Lanka</i> 		
9.30 am - 10.55 am	Genomic Diversity <ul style="list-style-type: none"> ▷ 9.30 am – 9.50 am Discovering the biology of major psychiatric illness in India <ul style="list-style-type: none"> ▷ Dr Biju Viswanath <i>National Institute of Mental Health and Neurosciences</i> ▷ 9.50 am - 10.10 am ENIGMA's Global Neuroimaging & Genomics Studies of 30 Brain Diseases: Lessons from India, China, Japan, & Pakistan <ul style="list-style-type: none"> ▷ Dr Paul Thompson <i>Keck School of Medicine, University of Southern California</i> ▷ 10.10 am - 10.30 am The Mexican Biobank Project and Population Medical Genomics in Latin America <ul style="list-style-type: none"> ▷ Dr Andres Moreno-Estrada <i>Advanced Genomics Unit, Cinvestav-Mexico</i> ▷ 10.30 am - 10.55 am Group Q&A Moderator: <ul style="list-style-type: none"> ▷ Dr Gabriela Repetto <i>Universidad del Desarrollo</i> 		
10.55 am - 11.15 am	Teabreak Networking Session (Foyer)		
Session 9			
11.15 am - 12.40 pm	Research in LMICs <ul style="list-style-type: none"> ▷ 11.15 am - 11.35 am Challenges and Opportunities for Genomics Research in Limited Resource Settings <ul style="list-style-type: none"> ▷ Dr Eva Maria Cutiongco-de la Paz <i>Institute of Human Genetics, National Institutes of Health, University of the Philippines and Philippine Genome Center</i> ▷ 11.35 am - 11.55 am Dr Janewit Wongboonsin <i>Division of Nephrology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand Renal division, Brigham and Women's Hospital, Boston, USA</i> ▷ 11.55 am - 12.15 pm Strategic Cohort Design for the Global South: Maximising Insights Whilst Minimising Costs <ul style="list-style-type: none"> ▷ Prof Nicki Tiffin <i>South African National Bioinformatics Institute, University of the Western Cape</i> 		

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
▷ 12.15 pm - 12.40 pm	Group Q&A Moderator: ▷ Ms Chen Mengji <i>World Health Organization</i> ▷ Prof Gunadi <i>Universitas Gadjah Mada</i>		
12.40 pm - 2.00 pm	Parallel Track 1: Lunch Time Industry Talk	Parallel Track 2: Lunch Time Industry Talk Presentation by Novartis	Parallel Track 3: Lightning Talk (Early Career Scientist) ▷ Oral Presenter 1 (15mins) ▷ Oral Presenter 2 (15mins) ▷ Oral Presenter 3 (15mins) ▷ Oral Presenter 4 (15mins) ▷ Oral Presenter 5 (15mins)
Session 10			
2.00 pm - 3.20 pm	Parallel Track 1: Genetic Counselling & Community Engagement	Parallel Track 2: From Cohorts to Data Validation	Parallel Track 3: Presentation by TwistBioscience
▷ 2.00 pm - 2.20 pm	Genomics screening initiatives tailored for the Singaporean community ▷ Ms Yasmin Bylstra <i>SingHealth Duke-NUS Institute of Precision Medicine</i>	Cohort data management and interpretation in an African setting ▷ Prof Nicola Mulder <i>University of Cape Town</i>	
▷ 2.20 pm - 2.40 pm	A cutting-edge translation program having impact in returning genomic research results ▷ Ms Mary-Anne Young <i>Garvan Institute of Medical Research</i>	Qatar Biobank: From Cohort to Clinics - Validating Data Integrity Across the Healthcare Spectrum ▷ Dr Fatima Qafoud <i>Qatar Biobank</i>	
▷ 2.40 pm - 3.00 pm	Genetic Counselling Care Pathway in the Development of Mainstreaming Genetic Testing in Malaysia ▷ Ms Yoon Sook Yee <i>GENETIX Cancer Research Malaysia</i>	Gearing an entire country for precision medicine ▷ Prof Andrew Morris <i>Health Data Research UK</i>	
▷ 3.00 pm - 3.20 pm	Group Q&A Moderator: ▷ Ms Breana Cham <i>KK Women's and Children's Hospital</i>	Group Q&A Moderator: ▷ Prof Sarah Bauermeister <i>University of Oxford</i>	
3.20 pm - 4.00 pm	Teabreak Networking Session (Foyer)		
Session 11			
4.00 pm - 5.20 pm	Parallel Track 1: Population Health	Parallel Track 2: Genomic Science in Cohorts	
▷ 4.00 pm – 4.20 pm	The intersection of precision medicine and population health ▷ Prof Tai E Shyong <i>Precision Health Research, Singapore</i>	A comprehensive exploration of the fully phased diploid Indian genome, unraveling its unique attributes within the Pan-Asian genetic landscape ▷ Prof Liu Jian Jun <i>Genome Institute of Singapore</i>	

Time	Grand Ballroom	Meeting Room	Wisteria & Camellia Villa
▷ 4.20 pm – 4.40 pm	Population genetics in an era of genomic health ▷ Prof Eimear Kenny <i>Icahn School of Medicine at Mount Sinai</i>	Large-scale cognitive health research in health and psychopathology ▷ Dr Max Lam <i>Precision Health Research, Singapore</i>	
▷ 4.40 pm – 5.00 pm	What do we learn by studying biomarkers in diverse populations? ▷ Dr Arash Etemadi <i>National Cancer Institute, NIH</i>	Dr Nicolas Bertin <i>Agency for Science, Technology and Research</i>	
▷ 5.00 pm – 5.20 pm	Group Q&A Moderator: ▷ Prof Carmencita D. Padilla <i>University of the Philippines Manila</i>	Group Q&A Moderator: ▷ Mr Peter Goodhand <i>Global Alliance for Genomics and Health (GA4GH)</i>	
5.20 pm	End of Programme Day 3		



Overview Of Sessions

Plenary 1: NHS Genomic Medicine Service – From Cohorts to Clinics

The talk will outline the experience in establishing the infrastructure and the underpinning policies and strategies to integrate genomics into the national health system in England. Integral to this will be the learnings from the 100,000 genomes project and our ongoing partnership with Genomics England.



Prof Dame Sue Hill
NHS England

Plenary 2: Singapore National Precision Medicine Programme - Value Creation for Health and the Economy

Precision Medicine offers the opportunity to transform healthcare and improve patient outcomes through more accurate disease risk prediction, identifying patient segments most likely to respond to specific interventions, and novel molecular mechanisms driving disease pathophysiology. To realize the benefits of Precision Medicine, the Singapore government established the National Precision Medicine Programme (NPM), a three-phase roadmap to i) Establish South East Asia's most deeply phenotyped cohort to support understanding of multi-ethnic Asian health, ii) Implement data-driven healthcare systems to identify groups at higher risk of disease and progression, iii) catalyse Singapore's precision medicine industry by uplifting local companies and attracting multi-national companies.

In NPM Phase 1, we generated the world's largest multi-ethnic Asian reference database (SG10K Health), which provided insights into genetic conditions prevalent in Asia and a resource for clinicians to use as a reference database to manage patients with genetic disease. NPM Phase 2 is currently underway to scale this genomic-phenotypic database to 100 000 Singaporeans (PRECISE-SG100K), linking genomic, phenotypic, and clinical outcome data. PRECISE-SG100K will contribute to address key questions about Asian health and disease, covering populations currently under-represented in public databases.

The talk will describe how NPM has adopted a whole-of-government and multidisciplinary approach to overcome implementation barriers and maximise the opportunities of precision medicine research.



Prof Patrick Tan
*Precision Health Research,
Singapore*

Plenary 3: Implementing genomic medicine into clinical practice – a national and international perspective

Over the past 10 years, genomic sequencing has transformed the traditional diagnostic process, providing faster, more accurate and cost-effective diagnosis to many. Translational research programs, such as Australian Genomics, have been key in generating the evidence for diagnostic and clinical utility, as well as cost-effectiveness across a range of clinical indications paving the way for healthcare system implementation. Simultaneously, collaborative efforts nationally and internationally, such as through the Global Alliance for Genomics and Health, have built infrastructure, standards and capacity to enable accurate interpretation of genomic variation at scale. As an exemplar, the International Precision Child Health Partnership (IPCHiP) is a collaboration between the Murdoch Children's Research Institute and three major international paediatric centres to advance child health and genomics to improve diagnosis, implement personalised treatment decisions, and develop new therapeutic targets and treatments that will benefit children around the world.



Prof Kathryn North
Murdoch Children's Research
Institute

Plenary 4: Implementing Genomic Medicine Towards Universal Health Coverage for All People

In 2018, the Global Genomic Medicine Collaborative that met in Cape Town, South Africa adopted the Cape Town Declaration on Implementing Genomic Medicine Towards Universal Health Coverage by 2030. The Collaborative is now drafting a plan of action that can take us there. In this talk I shall deal with the challenge ahead and the proposed actions. It is hoped that this would result in wider discussion and the development of an advocacy document that could be taken to all governments by the time of the World Health Assembly of the World Health Organization in May 2025.



**Prof Vajira
Dissanayake**
University of Colombo, Sri Lanka

Biobanks for Precision Medicine

This session aims to explore the pivotal role of biobanks in Asia, Europe and the USA and how they are facilitating the seamless transition from cohort studies to clinical application.



Prof John Chambers

Precision Health Research, Singapore



Prof Chen Zhengming

University of Oxford



Dr Geoffrey Ginsburg

All of Us Research Program, National Institutes of Health



Dr Lin Yen-Feng

National Health Research Institutes, Taiwan



Prof Aarno Palotie

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland and Broad Institute and Massachusetts General Hospital, Boston, USA



Prof Masayuki Yamamoto

Tohoku University Tohoku Medical Megabank Organization (ToMMo)



Prof Nahla Afifi

International Health Cohorts Consortium (IHCC)



Dr Geoffrey Ginsburg

All of Us Research Program, National Institutes of Health

Moderator

Moderator

Cancer Genetics

This session aims to inform healthcare professionals on recent discoveries related to the genetic basis of various cancers, and discuss the use of novel diagnostic tools to treat patients with the appropriate therapeutics.



Dr Philip Awadalla

Ontario Institute for Cancer Research



Dr Ho Weang Kee

University of Nottingham Malaysia/Cancer Research Malaysia



Prof Joanne Ngeow

National Cancer Centre Singapore



Dr Arash Etemadi

National Cancer Institute, NIH

Moderator

Complex Traits/Variant Resolution

This session aims to discuss traits and diseases that are affected by multiple genes and environmental influences. Analytical techniques for associating specific genetic variants with complex traits will be demonstrated.



Dr Ammira Al-Shabeeb Akil

Sidra Medicine



Dr Jimmy Lee

Institute of Mental Health



Prof Wong Limsoon

National University of Singapore



Dr Lim Weng Khong

Duke-NUS Medical School

Moderator

Data Driven Discovery

This session aims to highlight research discoveries accelerated by the advent of big data and global data sharing and collaboration among longitudinal population studies.



Dr Raghib Ali
Our Future Health



Dr Rob Yang
CartaBio Inc



Dr Heidi Rehm
Massachusetts General Hospital and
Broad Institute



Dr Thomas Keane
EMBL- European Bioinformatics Institute

Moderator

Ethics and Policy

This session aims to update researchers on the ethical and legal considerations as well as the implications surrounding data sharing and data analysis of an individual's genetic and genomic information.



Dr Angela Ballantyne
University of Otago



Dr Michaela Mayrhofer
BBMRI-ERIC



Prof Julian Savulescu
National University of Singapore



Prof Nicki Tiffin
South African National Bioinformatics
Institute, University of the Western Cape

Moderator

From Cohorts to Data Validation

This session will call to attention the complexities of cohort and participant data collection, large scale data management and analysis to prepare datasets for downstream health and biomedical research.



Prof Andrew Morris
Health Data Research UK



Prof Nicola Mulder
University of Cape Town



Dr Fatima Qafoud
Qatar Biobank



Prof Sarah Bauermeister
University of Oxford

Moderator

Genetic Counselling & Community Engagement

This session aims to highlight the vital role genetic counselors and community engagement plays in fostering meaningful connections between participants and scientists to maximise translational value.



Ms Yasmin Bylstra

SingHealth Duke-NUS Institute of Precision Medicine



Ms Yoon Sook Yee

GENETIX Cancer Research Malaysia



Ms Mary-Anne Young

Garvan Institute of Medical Research



Ms Breana Cham

KK Women's and Children's Hospital

Moderator

Genomic/Precision Medicine for Therapeutic R&D

This session aims to explore the application of genomic analyses to discover, validate and develop novel therapeutic targets, biomarkers and genes that affect the efficacy and safety of new medicines.



Dr Guillermo Del Angel

AstraZeneca



Dr Mark McCarthy

Genentech



Dr Lyndon Mitnaul

Regeneron Genetics Center



Dr Scott Sundseth

International Health Cohorts Consortium (IHCC)

Moderator

Genomic Diversity

Genomic diversity encompasses the vast array of genetic variations within human populations and has significant implications for research, healthcare and society. This session aims to explore the rich tapestry of genomic diversity and highlight its role in shaping individual traits and susceptibility to diseases.



Dr Andres Moreno-Estrada

Advanced Genomics Unit, Cinvestav-Mexico



Dr Paul Thompson

Keck School of Medicine, University of Southern California



Dr Biju Viswanath

National Institute of Mental Health and Neurosciences



Dr Gabriela Repetto

Universidad del Desarrollo

Moderator

Genomic Science in Cohorts

This session aims to explore how the cohort infrastructure can be used as a source for genomic research. It identifies the requirements for cohort studies, in terms of design, consent, and data and sample collection, to contribute to genomic science.



Dr Nicolas Bertin
Agency for Science, Technology and Research



Prof Liu Jian Jun
Genome Institute of Singapore



Dr Max Lam
Precision Health Research, Singapore



Mr Peter Goodhand
Global Alliance for Genomics and Health (GA4GH)

Moderator

Genomic Screening

This session aims to explore the use of genomic analysis technologies to deliver prognoses for both common and rare genetic diseases and what are the implications of the applications.



Dr Chien Yin Hsiu
National Taiwan University



Prof Martin Delatycki
Murdoch Children's Research Institute



Prof Thong Meow-Keong
Universiti Tunku Abdul Rahman



Dr Tan Ee Shien
Precision Health Research, Singapore

Moderator

Industry Speaker

Attend the Lunchtime Industry Talks, where industry experts will share valuable insights and the latest advancements. Connect with professionals and expand your knowledge at these informative sessions while you enjoy your lunch.



Dr Radoje (Rade) Drmanac
MGI Tech



Dr Kyle Farh
Illumina



Prof Lili Milani
Estonia Biobank, Estonian Genome Center, University of Tartu (PacBio)



Ms Cora Vacher
Oxford Nanopore Technologies

Pharmacogenomics

This session aims to explore the relationship between an individual's genotype and their response to medicines. Specific population data and regional implementation practices that have the potential for making better medication and dosing decisions will be presented.



Prof Collet Dandara

University of Cape Town



Dr Elaine Lo Ah Gi

National University Hospital



Prof Chonlaphat Sukasem

Ramathibodi Hospital, Mahidol University



Mr Grant M. Wood

Global Genomic Medicine Collaborative (GGMC)

Moderator

Population Health

This session aims to discuss the dynamics of population health within the context of the shifting global healthcare landscape, examining how population-level data can inform and enhance clinical practice, bridging the gap from cohorts to clinics.



Dr Arash Etemadi

National Cancer Institute, NIH



Prof Eimear Kenny

Icahn School of Medicine at Mount Sinai



Prof Tai E Shyong

Precision Health Research, Singapore

Moderator

Rare Diseases

Rare diseases pose unique challenges and collaboration is essential in addressing the complexities of rare diseases and to drive innovation in research and patient care. This session aims to facilitate dialogue between researchers and clinicians invested in advancing rare disease research.



Dr Claudia Gonzaga-Jauregui

International Laboratory for Human Genome Research, UNAM



Dr Saumya Jamuar

KK Women's and Children's Hospital



Dr Gabriela Repetto

Universidad del Desarrollo



Prof Duangrurdee Wattanasirichaigoon

Faculty of Medicine Ramathibodi Hospital, Mahidol University

Moderator

Research in LMICs

This session aims to encourage networking with and among researchers in low- and middle-income countries, identify challenges in these settings and foster the use of quality studies in such settings for precision medicine.



Dr Eva Maria Cutiongco-de la Paz

Institute of Human Genetics, National Institutes of Health, University of the Philippines and Philippine Genome Center



Prof Nicki Tiffin

South African National Bioinformatics Institute, University of the Western Cape



Dr Janewit Wongboonsin

Division of Nephrology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand | Renal division, Brigham and Women's Hospital, Boston, USA



Ms Chen Mengji

World Health Organization

Moderator



Prof Gunadi

Universitas Gadjah Mada

Moderator

Training/Early Career Scientists

This session is open to all Early Career Scientists and will delve into the essential components of nurturing and supporting emerging scientists as they navigate through multifaceted ecosystems that make up their academic and professional pathways.



Prof Richard Haspel

Beth Israel Deaconess Medical Center and Harvard Medical School



Dr Victoria Nembaire

University of Cape Town



Dr Sharon Plon

Baylor College of Medicine



Prof Michele Ramsay

University of the Witwatersrand

Moderator

*Speakers are arranged in alphabetical order based on their last names.

Accepted Abstracts

ID	Abstract title	Presenting Author(s)	Institution / Organisation	Poster Display
1	SEPT-GD: a decision tree to prioritise potential RNA splice variants in cardiomyopathy genes for functional splicing assays in diagnostics	Dr Mohamed Alimohamed	Muhimbili University of Health and Allied Sciences	
2	Single-cell analysis of human diversity in circulating immune cells	Dr Kock Kian Hong	Genome Institute of Singapore, Agency for Science, Technology and Research	
3	Understanding the purpose of prescribing is key for enabling shared decision-making with hospitalised patients on antibiotic therapy: A cross-sectional study in Singapore	Dr Angela Chow	Tan Tock Seng Hospital	
4	Transforming Genomics Research through Community Engagement: A Case Study from the Pukapuka Community in Aotearoa, New Zealand.	Dr Jaye Moors	Variant Bio	
5	Harnessing AI for Precision Antibiotics: Enablers and Ethical Considerations	Dr Angela Chow	Tan Tock Seng Hospital	
6	Identifying the unmet needs of Neurofibromatosis Type 1 patients in Singapore	Dr Agnes Lim	Singapore General Hospital	
7	Germline pathogenic variants landscape of endometrial cancer in Singapore	Dr Zhang Zewen	National Cancer Centre Singapore	
8	10K Newborn Genome Project in Qingdao, China: clinical findings and precision health insights	Dr Gao Ya	BGI Research	
9	Social factors and health: Cohort creation to design innovative, targeted intervention strategies and community care models	Dr Lim Wei-Yen	Tan Tock Seng Hospital	
10	Utilizing Asian Genomics Data to Identify Vulnerabilities in Hepatocellular Carcinoma Cells	Dr Michael Winther	Engine Biosciences	
11	Unlocking the potential of large-cohort proteomics studies with mass spectrometry-based proteomics solution	Dr Xuan Yue	Thermo Fisher Scientific	
12	Systematic Review on the Effectiveness of Risk-Based Screening for Cancer Diagnosis	Fahmy Fadzil	Nanyang Technological University	
13	Microfluidic isolation of complete platelet-free plasma for enhanced detection of blood extracellular vesicles (EV) microRNAs and surface proteins	Dr Leong Sheng Yuan	Nanyang Technological University	
15	Determination of genetic variants associated with Sarcoidosis in Sri Lankan Population	Sawani Rodrigo	University of Colombo	
16	TAS-PGx: Targeted Adaptive Sampling-Long Read Sequencing for Enhanced Pharmacogenomics Profiling and Genome-Wide Variant Analysis	Dr Mar Gonzalez-Porta	Nalagenetics	
17	Bridging Data and Clinical Decision-making: Case Study Analysis of Hepatocellular Carcinoma with Enhanced Microbiome Insights	Dr Damien Keogh	BluMaiden Biosciences	
18	A learning and training agenda with a global focus: Delivering large-scale knowledge and skills development in real-time	Dr Michelle Bishop	Wellcome Connecting Science	
19	Whole-genome sequencing of half-a-million China Kadoorie Biobank participants	Dr Jin Xin	BGI Research	
20	Addressing the 'Leaky Pipe' in Colorectal Cancer Genetics Referrals: The Critical Need for Optimization	Nur Diana Ishak	National Cancer Centre Singapore	
21	A modular approach to compiling data sharing agreements to promote more equitable terms for data sharing.	Dr Tsaone Tamuhla	South African National Bioinformatics Institute	
22	Nex Gen Sequencing-based proteomics and their utility in large population health cohorts	Dr Cynthia Lawley	Olink	
23	Decoding the molecular ageing spectrum of Asians and its clinical prospects in 10,018 Singaporeans	Dr Ives Lim	Bioinformatics Institute, Agency for Science, Technology and Research	
24	Spatial transcriptomic analysis of triple-negative breast cancer occurring during pregnancy and post-involution in women of African ancestry	Dr Victoria Seewaldt	City of Hope Comprehensive Cancer Center	
26	Broad-scale proteomics combined with genomics help identify early detection and causal biomarkers in cancer	Dr Cynthia Lawley	Olink Proteomics	
27	Genomic Insights into COVID-19 Susceptibility and Severity Among Singaporeans: A Multi-National Platform Initiative	Penny Chan	Bioinformatics Institute, Agency for Science, Technology and Research	
28	Is Genetic Testing Cost-effective to Detect and Manage Lynch Syndrome in Singapore?	Sara Tasnim	Lee Kong Chian School of Medicine, Nanyang Technological University	
29	Dietary risk factors for visceral adiposity in multiethnic Asian population: An epidemiological and metabolomics study	Dr Theresia Mina	Nanyang Technological University	
30	Multi-locus Inherited Neoplasia Alleles Syndromes in Cancer: An updated review and implications for clinical practice	Jeanette Yuen	National Cancer Centre Singapore	
32	Genetic counselling and testing for kidney disease by nephrologists – a single-center implementation study	Dr Lee Tung Lin	Singapore General Hospital	

ID	Abstract title	Presenting Author(s)	Institution / Organisation	Poster Display
33	Strategies to improve implementation of cascade testing in hereditary cancer syndromes: A systematic review	Dr Chiang Jianbang	National Cancer Centre Singapore, Medical Oncology	
34	Nephrologists' perspectives on facilitators and barriers of clinical implementation of genetic testing in Singapore	Ng Jun Li	National University of Singapore	
35	Understanding Women's Preferences for Undergoing Breast Cancer Risk Assessment: Insights from a Discrete Choice Experiment	Dr Wang Yi	Saw Swee Hock School of Public Health, National University of Singapore	
36	Beyond Lipid Profile: Enhancing Electronic Phenotyping with Unstructured Data	Meenakshi Dubey	National University of Singapore	
37	Adherence to risk management guidelines in individuals with hereditary cancer conditions in Singapore	Sowmya Jonnagadla	National Cancer Centre Singapore	
39	Vasculature damage and dysmetabolism in heart failure with preserved ejection fraction.	Wu Lik Hang	National University of Singapore	
40	Metabolic variation reflects dietary intake in a multi-ethnic Asian population	Dr Dorrain Low	Lee Kong Chian School of Medicine, Nanyang Technological University	
41	Creating an efficient and truly federated international data market for genomic and health data.	Dr Oriol Canela-Xandri	University of Edinburgh / Omecu Ltd.	
42	Bravo automation of Agilent Avida targeted enrichment for high-throughput detection of genomic alteration and DNA methylation	Dr Lee Chee Yang	Agilent Technologies Singapore	
43	Obesity increases susceptibility to symptomatic flaviviral infection and alters host response to infection	Dr Ayesa Syenina	Duke-NUS Medical School	
44	The use of optical genome mapping in prenatal evaluation for translocation carriers	Dr Chin Hui-Lin	National University Hospital	
45	Fetal Akinesia and biallelic variants in TNNI2	Dr Denise Goh Li Meng	National University of Singapore	
46	Precision Medicine for Diabetic Individuals: A Joint Malaysia-UK Effort (PRIME) exploiting a multi-ethnic cohort resource for clinical applications	Dr Rahman Jamal	UKM Medical Molecular Biology Institute (UMBI, Universiti Kebangsaan Malaysia)	
47	A proposed framework prioritizing pharmacogenomic drug-gene interactions in an Asian context for chemotherapy	Dr Janice Goh	Bioinformatics Institute, Agency for Science, Technology and Research	
48	Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack	Dr Kaavya Narasimhalu	National Neuroscience Institute	
49	Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D	Dr Ken Chong	Bioinformatics Institute, Agency for Science, Technology and Research	
50	Cascade testing for hereditary cancer in Singapore: how population genomics help guide clinical policy	Dr Rebecca Caeser	National Cancer Center Singapore	
51	Genetic model predicts lifelong cardiometabolic risks in women.	Dr Pan Hong	Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research	
52	Whole genome sequencing reveals a high incidence of germline pathogenic variants in genes associated with sarcoma across subtypes	Isaac Lin	Lee Kong Chian School of Medicine, Nanyang Technological University	
53	STCC Unified PD1/PD-L1 Evaluation of Response (SUPER) – a Use-Case Study of the Translational Research Integration and Support Platform	Dr Michał Marek Hoppe	Singapore Translational Cancer Consortium	
54	Unlocking Skin's Defenses: Repurposing Belinostat for Atopic Dermatitis Treatment	Dr Gowtham Subramanian	Agency for Science, Technology and Research	
55	An End-to-end Privacy-preserving Framework for Predicting Cancer Outcomes	Dr Sim Jun Jie	Institute for Infocomm Research	
56	Understanding baseline determinants for mRNA vaccine immunogenicity	Dr Christine Tham	DUKE-NUS Medical School	
57	Statin Lactone Metabolism is a Determinant of 5-year Cardiovascular Outcomes Independent of Serum Cholesterol	Eugene goh	National University of Singapore	
58	Genetic Architecture of plasma metabolites in the Southeast Asian population	Dr Pritesh Jain	Lee Kong Chian School of Medicine, Nanyang Technological University	
59	Phenotypic variability in Ornithine Transcarbamylase deficiency males with the OTC R277W variant: A case report and review of the literature.	Shreya Surendra Shetty	Division of Genetics and Metabolism, Department of Paediatrics, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital	
60	The Dementias Platform UK (DPUK) IHCC Remote Mentoring Programme: Democratizing collaboration and mentoring for Early Career Researchers (ECRs)	Dr Sarah Bauermeister	University of Oxford	
61	Cascade screening for family members of patients with Familial Hypercholesterolemia in Singapore: FHCARE program	Madhuumetaa Selvakumar	Khoo Teck Puat Hospital	
62	Targeted Full-Genomic Gene Panel as Diagnostics for Uncovering Deep Intronic Variants in Genetic Disorders	Cher Wei Yuan	Institute of Molecular and Cell Biology, Agency for Science, Technology and Research	

ID	Abstract title	Presenting Author(s)	Institution / Organisation	Poster Display
63	Spectrum of Compound Heterozygous, Double Heterozygous and Homozygous variants in Index Patients with Familial Hypercholesterolemia in Singapore	Chen Hoe Meng	Clinical Research Unit, Khoo Teck Puat Hospital	
64	To test or not to test? A measure of informed choice for Hereditary Breast and Ovarian Cancer Syndrome testing	Chua Zi Yang	National Cancer Centre Singapore	
65	From cohorts to the clinic: interactively visualising amyotrophic lateral sclerosis (ALS) future risk projections	Dr Jane Ong Siying	Singapore Institute of Clinical Sciences, Agency for Science, Technology and Research	
66	Cost-effectiveness of Pre-emptive Pharmacogenetic Panel Testing versus No Testing in a Multi-ethnic Asian Population	Jamaica Roanne Briones	National University of Singapore	
67	Genomic co-localisation, child proteomics and brain imaging support a link between obesity-associated genotype and child language development.	Dr Huang Jian	Singapore Institute for Clinical Sciences	
68	From Cohort to Clinic: Return of genetic incidental findings in the population-based Multi-Ethnic Cohort	Dr Sim Xueling	Saw Swee Hock School of Public Health, National University of Singapore	
71	A Partially Connected Neural Network for Enhanced Polygenic Risk Score Prediction	Dr Weng Haoyi	WeGene	
72	Telomere Length Distribution and Genome-wide Association Study Among Singaporean Cohorts	Trang Nguyen	Nanyang Technological University	
73	Plasma proteomic signatures of adiposity are associated with cardiovascular risk factors and type 2 diabetes risk in a multi-ethnic Asian population.	Dr Charlie Lim	Saw Swee Hock School of Public Health, National University of Singapore	
74	Metabolome-wide association of carotid intima media thickness in an Asian population cohort identifies FDX1 as a determinant of cholesterol metabolism and cardiovascular risk.	Dr Nilanjana Sadhu	Lee Kong Chian School of Medicine, Nanyang Technological University	
75	Integrative analysis of omics summary data reveals putative mechanisms underlying dilated cardiomyopathy	Konstanze Tan	Lee Kong Chian School of Medicine, Nanyang Technological University	
76	Leveraging existing large-scale genomic studies for assessment of genetic risk within Singapore	Ashley Lim Jun Wei	National University of Singapore / Illumina Inc.	
77	Necessity of case-control joint calling for accurate evaluation of rare variant disease contribution	Neo Jun Hao	National University of Singapore	
78	Can polygenic risk scores from different genotyping arrays be used interchangeably?	Dr Ho Peh Joo	Genome Insititute of Singapore	
79	Predictors for Positive Genetic Diagnosis of Monogenic Kidney Disease.	Dr Regina Lim Shaoying	Tan Tock Seng Hospital, National Healthcare Group	
80	Early life proteomic markers for child depressive symptoms	Che Jinyi	Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research	
81	Genetics and Genomics Education Programmes in Singapore	Dr Koh Ai Ling	KK Women's and Children's Hospital, SingHealth	
82	Association of thyroid peroxidase antibodies and high-sensitivity C-reactive protein: a cross-sectional analysis from the ELSA-Brasil study	Dr Isabela Bensenor	Universidade de São Paulo	
83	Thyroid peroxidase antibodies are associated with incidence, but not progression, of coronary artery calcification: analysis of the ELSA-Brasil cohort study	Dr Isabela Bensenor	Universidade de São Paulo	
84	Constructing a 3D anatomical atlas of hepatic vasculature variants for surgical planning	Dr Too Chow Wei	Singapore General Hospital	
85	The Genetic Heterogeneity & Phenotypic Continuum of Developmental and Epileptic Encephalopathies: Data from a Sri Lankan Cohort	Dr Hasani Hewavitharana	Lady Ridgeway Hospital for Children, Ministry of Health	
86	De-novo Sub-clustering of Young-Onset Type 2 Diabetes Identify Subgroups with Distinct Clinical Characteristics	Kee Kai Xiang	Khoo Teck Puat Hospital	
87	Circulating proteomic profiles are associated with the onset of type 2 diabetes in a multi-ethnic Asian population – a longitudinal study	Dr Liang Yujian	National University of Singapore	
88	Deciphering the Epigenetic Role of Small Non-coding RNA in Obesity	Felicia Tin	Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research	
89	Can deep learning-based retinal omics personalise cardiovascular disease prediction?	Chan Yarn Kit	Duke-NUS Medical School	
90	Coronary calcium score levels and risk for fatal and non-fatal cardiovascular events – the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)	Dr Isabela Bensenor	Center for Clinical and Epidemiological Research, University Hospital, University of São Paulo, São Paulo, Brazil	
92	Nurturing minds, nourishing bodies: Associations between maternal mental health, feeding practices and child eating behaviours in the GUSTO cohort.	Dr Anna Magdalena Fogel	Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research	
93	Predicting early-life BMI Trajectories through Proteomics Data by learning Parametric Koopman Decomposition	Dr Chen Yurui	Department of Mathematics, National University of Singapore, and Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research	

ID	Abstract title	Presenting Author(s)	Institution / Organisation	Poster Display
94	Public expectations about the public interest of research	Dr G. Owen Schaefer, Marthe Smedinga, Toh Hui Jin	Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore	
95	Spectrum of FBN1 Variants and Their Phenotypic Correlations in a Cohort of Twelve Sri Lankan Patients	Dr Yasas Dahamuna Kolambage	Sabaragamuwa University of Sri Lanka	
96	Evaluating quantitative proximity extension assay as a monitoring tool for precision health	Dr Eugenia Ong	Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS / Duke-NUS Medical School	
97	Next generation proteomic profiling of a pan-cancer cohort for the development of screening tools for cancer	Dr Renu Balyan	Olink Proteomics	
98	Severe Combined Immunodeficiency (SCID) Screening in Singapore	Sherry Poh	KK Women's and Children's Hospital	
99	The Human Gut Microbiome in Pregnancy and Early Life: Insights from the GUSTO and S-PRESTO multi-ethnic Asian Cohorts	Dr Xu Jia	Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research	
100	Comparing Polygenic risk, Elastic Nets and Interpretable Artificial Intelligence Approaches in the Prediction of Vitamin D Insufficiency in Pregnant Women and their Children	Dr Geoffrey Tan	Institution of Mental Health Singapore	
101	Genetic adaptations of humans to the diverse environments of South America	Dr Amit Gourav Ghosh	Singapore Centre for Environmental Life Sciences Engineering (SCELSE), NTU	
102	Virtual panels have a superior diagnostic yield for inherited rare diseases relative to static panels	Dr Massy Sheikh Hassani	Al Jalila Children's Hospital	
103	From North Asia to South America: Tracing the longest human migration through genomic sequencing	Dr Kim Hie Lim	Nanyang Technological University	
104	The Nile Delta of Precision Medicine: Prenatal Genomic Care in Highly Inbred Population	Dr Mohammed Alowain	King Faisal Specialist Hospital and Research Centre	
106	Genomics for KIDS in ASEAN: Improving access to genomic medicine for paediatric rare disease in Southeast Asia	Dr Chan Sock Hoai	KK Women's and Children's Hospital	
107	Defining and Reducing Variant Classification Disparities Across Human Populations	Dr Irene Gallego Romero	St Vincent's Institute of Medical Research	
108	Higher blood biochemistry-based biological age developed by advanced deep learning techniques is associated with frailty in geriatric rehabilitation inpatients: RESORT	Dr Guan Lihuan	National University of Singapore	
109	The Federated EGA: A global network for discovery and access for sensitive human data	Dr Thomas Keane	EMBL European Bioinformatics Institute	
110	Clinical Benefits of CYP2C19 Genotype-Guided Therapy of Antiplatelets against Standard Care in Stroke Patients: Meta-Analysis	Dr Mohitosh Biswas	University of Rajshahi	
111	Lipidomic signatures of insulin resistance and metabolic flexibility in Asian subjects identified from hyperinsulinemic-euglycemic clamp studies	Dr Sartaj Mir	National University of Singapore	
113	Advancing Personalized Medicine and Public Health: The Role and Impact of Qatar Biobank	Dr Marwa Eldeeb	Qatar Biobank	
114	A 15-year Pharmacogenomics Tests in a Thai Pharmacogenomic and Personalized Medicine Center	Maliheh Ershadian	Mahidol University	
115	Analysis of 100,000 Whole Genomes Reveals Genetic Basis of Pregnancy Phenotypes and Complications in Chinese Population	Dr Zhu Huanhuan	BGI Research	
116	Unlocking Medical Insights through the Power of Taiwan Biobank Whole Genome Data	Dr Jacob Shujui Hsu	National Taiwan University	
117	Familial coaggregation and shared genetic loading of psychiatric and gastrointestinal disorders	Dr Pan Yi-Jiun	School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan	
118	Incorporating polygenic liability and family history for predicting psychiatric diseases in the Taiwan biobank	Dr Wang Shi-Heng	National Center for Geriatrics and Welfare Research, National Health Research Institutes, Miaoli, Taiwan	
119	Gene therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec: real-world experience, challenges and ethical concern in Malaysia	Dr Tae Sok Kun	University Malaya	
120	Bridging Gaps in Genomic Research: Insights from Diverse Indonesian Populations	Dr Pradiptajati Kusuma	Mochtar Riady Institute for Nanotechnology	
121	CREATION OF THE PHILIPPINE LIST OF RARE DISEASES USING A SCORING SYSTEM	Dr Ebner Bon Maceda	Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila	
122	XY Leap Clinical Decision Support Software delivers DNA-guided Individualized Medicine 3.0 therapeutics at Point-of-Care	Dr Andrew Winnington	Precision Medicine International Limited	
124	Pharmacogenomics at Scale: Database Construction and Variation Analysis of 257 Pharmacogenes from a Chinese Newborn Cohort with 6,442 Individuals	Dr Jian Min	BGI Research	

ID	Abstract title	Presenting Author(s)	Institution / Organisation	Poster Display
125	Pharmacogenetic Variability of UGT2B7, CYP3A4, CYP3A5 and CYP2B6 Genes in an American American Sickle Cell Disease Patient Cohort	Dr Cheedy Jaja	University of South Florida	
126	Genetic Counseling for Sickle Cell Hemoglobinopathies in Sub-Saharan Africa: A Nursing Champion Implementation Science Study Protocol	Dr Cheedy Jaja	University of South Florida	
127	Large-scale protein-disease risk association analysis in the UK Biobank: Introducing an extensive and freely available research resource in Olink® Insight	Dr Renu Balyan	Olink Proteomics	
128	Genetic Variants on Genes Related to Endomembrane System are Associated with Longevity	Dr Li Yan	BGI Research	

Sponsors and Partners

Platinum



Gold



Silver



Advancing Genomics, Improving Life



Bronze



Academic and Healthcare Partners



Supporting Partners



Sponsors are arranged in alphabetical order.

Platinum Sponsor

Illumina

ILLUMINA INDUSTRY TALK

Artificial Intelligence

for precision medicine and drug discovery


Performing biological interpretation experiments enables you to capture critical knowledge on biological processes, disease origins, and novel genetic biomarkers.

Illumina provides powerful, integrated interpretation solutions to streamline the journey from sample to answer, enabling you to deliver greater impact, with greater efficiency.

Population studies

Global and other large-scale genomic initiatives are generating genomic and multiomic insights by sequencing and analyzing millions of samples across diverse populations.

Learn more about how state-of-the-art bioinformatics tools from Illumina leverage the power of AI, third-party knowledge sources, and customizable reporting to streamline the path from an NGS sample to a research report.



illumina®

For Research Use Only. Not for use in diagnostic procedures.



Kyle Farh MD, PhD


VP & Distinguished Scientist has been at Illumina since 2015 and leads the Artificial Intelligence lab at Illumina. The AI lab has been responsible to a large extent for the adoption of deep learning in clinical variant interpretation, including the pioneering SpliceAI and PrimateAI-3D algorithms, two widely used AI tools for clinical interpretation of human genetic variants.

When: 22nd Aug
12:40 - 2:00pm

Where: Parallel Track 1
Lunch Time Industry Talk
Grand Ballroom

Platinum Sponsor

Illumina



Learn more about our complete solution for biobank-scale genetic cohorts

1

SEQUENCING PLATFORM

- ✓ Instrument
- ✓ Library prep
- ✓ Reagents

2

SOFTWARE ECOSYSTEM

- ✓ DRAGEN™ secondary analysis
- ✓ Illumina Connected Analytics (ICA)
- ✓ Emedgene™
- ✓ Illumina Connected Insights (ICI)

3

AI AND SCIENTIFIC SERVICES

Illumina's scientific team provides leading precision medicine and drug discovery insights for biobank-scale genetic cohorts.




Visit the Illumina booth to talk to our expert team.

For Research Use Only. Not for use in diagnostic procedures.

illumina®

Platinum Sponsor

MGI Tech



Meet us at PRECISE-IIHCC Conference 2024 at Booth B06

Grand Ballroom

Day 1 (21 August 2024, Wednesday, between 12.00pm – 1.30pm SGT)
Slot 2, 12.55pm – 1.20pm (SGT), MGI

[More Info](#)



Platinum Sponsor

MGI Tech



MGI

DCS LAB

Unlock the Future of Healthcare with Large-scale Multi-omics

From single-cell analysis to population genomics, our platform enables the comprehensive digitization of human health. By integrating multiscale data, we provide unprecedented insights into the medical essence of each individual. Healthcare can now be truly personalized, predictive, and preventive, transforming the way we think about health and disease.

Powered by DNA, Cell and Spatial-omics Technology

DNA Omics **Cell Omics** **Spatial Omics**

More Info



Platinum Sponsor

PacBio

PacBio

WHY DO WHAT EVERYONE ELSE IS DOING?

TRY SOMETHING NEW.

PACBIO LONG-READ SEQUENCING LETS YOU UNDERSTAND DISEASE AND UNRAVEL BIOLOGY IN A WHOLE NEW WAY.



RARE +
INHERITED
DISEASE



PANGENOME
REFERENCE



WHOLE
GENOME
SEQUENCING



METHYLATION
PROFILING



TARGETED
SEQUENCING



www.pacb.com

Research use only. Not for use in diagnostic procedures.

Platinum Sponsor

PacBio

PacBio WHOLE GENOMES WHOLE POPULATIONS

LONG-READ SEQUENCING
FOR DIVERSE DISCOVERY



www.pacb.com

Research use only. Not for use in diagnostic procedures.

Gold Sponsors

BC Platforms



FROM DATA TO HEALTH

Join the Partnership for Innovation in
Precision Medicine and Life Science.

Harness the power of our leading technology
to transform data into life-saving solutions
for patients.

www.bcplatforms.com



Gold Sponsors

Novartis

Continuous and sustained **SMN protein expression** with a one-time dose¹



REFERENCE 1. Zolgensma® Singapore Prescribing Information Nov 2023.

 NOVARTIS | Reimagining Medicine

Novartis (Singapore) Pte Ltd
20 Pasir Panjang Road #10-25/28, Mapletree Business City
Singapore 117439
P +65 6722 6010 | F +65 6323 4335 | W www.novartis.com.sg
FA-11218380 | JUNE 2024

Please visit <https://www.novartis.com/sg-en/product-list/zolgensma> to access or download the Package Insert.

Alternatively, please scan this QR code for more information about this medicine.

For Healthcare Professionals only.



 zolgensma®
(onasemnogene
abeparvövec)

Gold Sponsors

Olink



Olink®

Revealing the truth
of human disease.
Protein by protein.

Olink is committed to accelerating proteomics together with the scientific community and providing deeper understanding of real-time biology in human health and disease. This is enabled through the ground-breaking Proximity Extension Assay (PEA) technology, a uniquely scalable proteomics solution that empowers seamless transition from large-scale biomarker discovery to the development and validation of protein signatures with clinical utility.

www.olink.com

© 2024 Olink Proteomics AB.
Olink products and services are For Research Use Only and not for Use in Diagnostic Procedures. This document is not intended to convey any warranties or representations of any kind.
1506_v1.0, 2024-06-04

Gold Sponsors

Oxford Nanopore Technologies

WHAT YOU'RE MISSING MATTERS

ASK BOLDER QUESTIONS. BE THE FIRST TO UNCOVER NOVEL BIOLOGY.

Oxford NANOPORE Technologies

Oxford Nanopore Technologies and the Wheel icon are registered trademarks of Oxford Nanopore Technologies plc. All rights reserved. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.

Groundbreaking speed. Any-length sequencing reads. Rich datasets, including epigenetic information, fusions, structural variations, and more. You'll never see sequencing the same way again.


QR code

Gold Sponsors**Nightingale Health****Nightingale Health**
For Research**Practically the best 'omics**

Nightingale Health offers affordable metabolomics and scalable remote blood collection. Measure more than 250 biomarkers that cover core human metabolism, including 39 clinically validated biomarkers from just €24 per sample. We've analyzed all half a million samples in the UK Biobank, and our technology is now used in healthcare nation-wide in Finland.

CoreMetabolomics


by Nightingale Health



Measuring every sample gives you
the most freedom to explore.

RemoteOmics

by Nightingale Health



Reliable self-collected blood samples
take multi-omics research everywhere.

Visit our booth and learn more :

ngh.site/precise-ihcc

Mention this ad at our booth and get a surprise!

LB-0428 06/2024

Gold Sponsors**SomaLogic**

Advancing population proteomics: from *discovery* to *development*

Accelerate biomarker discovery, validation and development with the SomaScan® Platform, providing **scalability of content and highly reproducible data overtime**.

Advance your large population studies by profiling 11,000 protein measurements from a 55 µL sample and **turn raw data into meaningful biological insights**.



Learn more about how we advance proteomic innovation
[Somalogic.com/Large-Population-Proteomics-Singapore](https://somalogic.com/Large-Population-Proteomics-Singapore)

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks.

SomaLogic, SomaScan, SOMAmer, SomaSignal, DataDelve and associated logos are trademarks of SomaLogic Operating Co., Inc., a wholly owned subsidiary of Standard BioTools Inc. Patent and Trademarks: <https://somalogic.com/list-of-patents/>. Any other trademarks are the sole property of their respective owners.

©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Silver Sponsors

NovogeneAIT Genomics

Your Trusted Genomics Partner

**Genomics · Transcriptomics · Single Cell Omics
· Metagenomics · Epigenomics · Proteomics**

NovogeneAIT Genomics is a leading multi-omics services and solutions provider headquartered in Singapore. It is formed as a strategic joint venture between Novogene and AITbiotech, in 2016. Operating from our state-of-the-art sequencing center in Singapore, we are dedicated to advancing genomic research by offering unmatched data quality that empowers researchers across diverse sectors, including healthcare and agriculture, to realize their research goals. visit novogene.com/amea-en.

NovogeneAIT


Learn more about our services and promotions.



Twist Bioscience

More Targets, Fewer Reads

Twist RNA Exome detects more targets with fewer reads over a range of RNA inputs with FFPE and universal human reference RNA. All libraries were prepared with the Twist RNA Library Prep.



Sample Type	1 ng	10 ng	100 ng
Whole Transcriptome	~13,500	~14,800	~14,800
Twist RNA Exome	~14,800	~15,500	~15,500

Scan QR code to find out more about Twist RNA Sequencing Solutions.




Bronze Sponsors

Agilent Technologies



More Insights in Sights

Advancing precision oncology research



Agilent SureSelect Cancer Product Portfolio

Tumor genomic profiling solutions

- Globally curated catalog cancer assays and panels
- Customized cancer panels for assessing new and emerging biomarkers
- Walkaway automation with 15 minutes of hands-on time for increased efficiency
- Sample input as low as 10 ng for expanded profiling capacity
- Flexible data analysis options for novice to advanced users



For Research Use Only. Not for use in diagnostic procedures.
P/N 501-2589

Inqaba Biotec



UNIQUELY AFRICAN

CUTTING EDGE DNA SEQUENCING AND

GENOTYPING SERVICES @ INQABA BIOTEC!

We offer services on Revio and Onso instruments from PacBio to produce HiFi long-read and high quality short-read sequence data, respectively.

- NGS SEQUENCING SERVICES ON PACBIO REVIO & ONSO
- SANGER DNA SEQUENCING
- BIOINFORMATICS SUPPORT
- MICROARRAY & MASSARRAY SERVICES
- DNA SYNTHESIS (OLIGOS & PROBES)
- PROJECT MANAGEMENT



Use inqaba biotec - a PacBio certified service provider!

Contact us on: info@inqababiotec.co.za or +27 12 343 5829



JLABS

Apply to become a JLABS resident



JLABS Singapore was introduced in October 2023 as a groundbreaking collaboration between Johnson & Johnson Innovation and the Singapore Economic Development Board. This collaboration aims to support companies in Singapore by accelerating the translation of their early-stage discoveries into innovative medicines, medical technologies, and healthcare solutions.

Find out more at jnjinnovation.com or apply to become a resident at jji.jnj/apply



Macrogen Asia Pacific



Humanizing Genomics
macrogen
APAC



Bronze Sponsors

Sanofi



Academic and Healthcare Partners

A*STAR Biomedical Research Council (BMRC)



Charting New Frontiers In Genomic Science To Improve Human Health

A*STAR's Genome Institute of Singapore (GIS) is a national initiative with a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. As the producer, custodian, and curator of Singapore's genomic data, GIS leverages core capabilities in high quality sequencing and large-scale genome informatics, applied through four nucleic acid domains, to achieve impact for A*STAR, Singapore and the world.

At A*STAR's GIS, we are driving the next frontier in genomic science, from investigating genetic disorders to exploring new therapies. Collaborate with our world-class researchers and leverage cutting-edge technologies to unravel the mysteries encoded in our DNA. Join us at the forefront of genomic discovery to revolutionize genomic research and unlock the secrets of life itself.

Read more about our scientific discoveries and research work in genomic science and precision medicine, in collaboration with our partners in these publications:

- **Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore** ([https://www.cell.com/cell/fulltext/S0092-8674\(19\)31070-0](https://www.cell.com/cell/fulltext/S0092-8674(19)31070-0)) 
- **Accurate somatic variant detection using weakly supervised deep learning** (<https://www.nature.com/articles/s41467-022-31765-8>) 
- **RNA structure profiling at single-cell resolution reveals new determinants of cell identity** (<https://www.nature.com/articles/s41592-023-02128-y>) 

Follow GIS at:

Website: www.a-star.edu.sg/gis

LinkedIn: www.linkedin.com/company/genome-institute-of-singapore

Twitter: twitter.com/astar_gis

YouTube: www.youtube.com/@genomeinstitutesingapore

Academic and Healthcare Partners

Duke-NUS Medical School



GREATER
THINGS
HAPPEN *here*



Academic and Healthcare Partners

National University Health System

NATIONAL UNIVERSITY HEALTH SYSTEM
IS RANKED

9TH WORLD'S STRONGEST ACADEMIC MEDICAL CENTRE BRAND*

NUHS
National University
Health System

 National University Hospital	 Ng Teng Fong General Hospital	 Alexandra Hospital
 Jurong Community Hospital	 National University Polyclinics	 Jurong Medical Centre
 National University Cancer Institute Singapore	 National University Heart Centre Singapore	 National University Centre for Oral Health Singapore
 NUHS Diagnostics	 NUHS Pharmacy	 NUHS National University Health System Regional Health System Office
 Yong Loo Lin School of Medicine	 Faculty of Dentistry	 Saw Swee Hock School of Public Health

*Based on the Brand Finance AMC 250 2024 Report

Academic and Healthcare Partners

NUS Yong Loo Lin School of Medicine



Academic and Healthcare Partners

NTU Lee Kong Chian School of Medicine



#CohortstoClinics



for.sg/preciseihcc



International Health
Cohorts Consortium